Profusa, Inc. (PFSA) had quite the Friday rally after announcing its Healthcare Research version of the Lumee tissue oxygen monitoring system is now available for commercial use. The stock climbed 20.30% to $0.12, trading on volume that would make any trader do a double-take.
We're talking 140.93 million shares changing hands compared to the usual 25.7 million. That's the kind of volume spike that says something caught the market's attention.
What caught that attention? Profusa is making its Lumee tissue oxygen products available to contract research organizations, a market that's not exactly small potatoes. Industry projections show the CRO space growing from roughly $47.9 billion in 2025 to more than $91.2 billion by 2034, representing a compound annual growth rate north of 7%.
The strategy here is straightforward: offer the technology as research-use-only kits so CRO partners can integrate it into existing study designs without major implementation headaches. This opens the door to immediate service-based revenue while potentially improving drug development efficiency through real-time biological data.
For researchers and R&D teams, the system delivers continuous, real-time tissue oxygenation measurements. The applications span advanced in vitro and organ-on-chip models, preclinical pharmacology and toxicology studies, and translational research programs. Profusa has brought on Sean Givens to lead the commercialization push, highlighting what the company says is strong industry interest in their validated sensors.
